Project Group B: metabolic and systemic effectors

Project group B addresses relevant metabolic effector mechanisms and systemic crosstalk after AMI in an attempt to understand AMI as a systemic disease. To achieve this, the CRC 1116 focuses on type 2 diabetes mellitus (T2DM) and associated metabolic disorders such as non-alcoholic fatty liver, insulin resistance, prediabetes as well as effects of visceral and epicardiac adipose tissue. In addition to metabolic effector mechanisms, the contribution of immune mechanisms, clinical relevant comorbidities, such as anemia and mechanisms of remote cardiac conditioning will be analyzed.

Project B01 (Schrader/Scheller)

The CD73-adenosine-Interleukin 6-type cytokines axis in myocardial infarction

Project B05 (Szendrödi/Westenfeld)

Mitochondrial efficacy in AMI: role of PGC-1α

Project B06 (Jung/Kelm)

The circulating nitric oxide pool and anemia in acute myocardial infarction

Project B08 (Kleinbongard/Heusch)

Cardioprotection by ischemic conditioning in pigs with a metabolic syndrome

Project B09 (Gerdes)

Co-stimulatory molecules as determinants of the acute immune response following cardiac ischemia reperfusion (IR) injury

Project B10 (Grandoch/Flögel)

Unraveling the role of brown adipose tissue in myocardial ischemia/reperfusion injury

Project B11 (Levkau/Polzin)

Cardioprotection by functional and dysfunctional High-density lipoproteins (HDL) in comorbidities: molecular mechansims and therapeutic exploitation

Project B12 (Roden/Kelm)

Insulin resistance, diabetes and metabolic liver diseases in acute myocardial infarction

Responsible for the content: